Request an invite

Emrelis: which tox species, and why?

telisotuzumab vedotin · c-Met
Species
Cynomolgus monkey (relevant); rat non-binding (exploratory, MMAE-related effects)
“In addition, these studies support the use of cynomolgus monkey as the pharmacologically relevant species for toxicity assessments of telisotuzumab vedotin.”
✓ VerifiedFDA multi-discipline review, p. 33Source ↗
Why that species
Binds human and monkey c-Met with similar EC50 (1.3 vs 1.5 nM); no binding to mouse, rat, rabbit c-Met
“In vitro, telisotuzumab bound to cells overexpressing human or monkey c-Met with EC50 values of 1.3 and 1.5 nM, respectively, but did not bind to cells expressing mouse, rat, or rabbit c-Met.”
✓ VerifiedFDA multi-discipline review, p. 33Source ↗
Surrogate molecule
No surrogate; clinical ADC in monkey; MMAE payload data via Seagen right of reference
“The Applicant used information on the pharmacology, pharmacokinetics (PK), and toxicology profile of MMAE provided via right of reference from Seagen.”
✓ VerifiedFDA multi-discipline review, p. 33Source ↗

Same question, other ADCs

Adcetris

brentuximab vedotin · CD30
Rat and cynomolgus monkey (monkey the antigen-binding species)

Besponsa

inotuzumab ozogamicin · CD22
Rat and cynomolgus monkey (neither cross-reactive; target-independent toxicity only)

Datroway

datopotamab deruxtecan · Trop-2
Rat (non-binding) and cynomolgus monkey (relevant); DXd payload in rat and monkey

Decnupaz

pivekimab sunirine · CD123
Cynomolgus monkey (no CD123 cross-reactivity; off-target/payload toxicity) plus rat for FGN849 payload

Elahere

mirvetuximab soravtansine · FRα
Cynomolgus monkey (general tox); rabbit for ocular tox; DM4 payload in monkey and mouse

Enhertu

fam-trastuzumab deruxtecan · HER2
Cynomolgus monkey (relevant) plus rat (non-binding species)

Kadcyla

ado-trastuzumab emtansine · HER2
Rat and cynomolgus monkey (monkey pharmacologically relevant; long-term studies in monkey)

Mylotarg

gemtuzumab ozogamicin · CD33
Rat and cynomolgus monkey (neither pharmacologically relevant; no CD33 cross-reactivity)

Padcev

enfortumab vedotin · Nectin-4
Rat and cynomolgus monkey

Polivy

polatuzumab vedotin · CD79b
Rat and cynomolgus monkey (monkey with clinical ADC plus monkey-CD79b surrogate ADC)

Tivdak

tisotumab vedotin · Tissue factor
Cynomolgus monkey only for ADC; rat and monkey for MMAE payload

Trodelvy

sacituzumab govitecan · Trop-2
Cynomolgus monkey only (mouse for target-independent toxicity only)

Zynlonta

loncastuximab tesirine · CD19
No pharmacologically relevant species; cynomolgus monkey (non-binding) for ADC; rat and dog for payload SG3199

Summary across all 14 ADCs →